Zealand Pharma A/S (ZEAL)
- GlobeNewswire
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, June 15, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manager
- GlobeNewswire
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Credit Suis
- GlobeNewswire
Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity
COMPANY ANNOUNCEMENT – NO. 27/ 2022 Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity Phase 1 trial showed multiple doses of dapiglutide were well-tolerated and data supports once-weekly dosingInvestigator-Initiated Phase 2 trial of dapiglutide in obesity anticipated to commence by early 2023Data presentations for dapiglutide and other pipeline progra
